Restoration of fragile histidine triad expression restores Chk2 activity in response to ionizing radiation in oral squamous cell carcinoma cells

Cancer Science

Volumn 99, Issue 3, 2008, Pages 524-530

  Yutori, Hirokazu ^a   Semba, Shuho ^a   Komori, Takahide ^a   Yokozaki, Hiroshi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 2; DNA; FRAGILE HISTIDINE TRIAD PROTEIN; MUTANT PROTEIN; PROTEIN TYROSINE PHOSPHATASE; SMALL INTERFERING RNA; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INCIDENCE; CANCER INHIBITION; CARCINOGENESIS; CELL POPULATION; CELL STRAIN HEK293; CONTROLLED STUDY; DNA DAMAGE; DOWNSTREAM PROCESSING; DYSPLASIA; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FORESTOMACH; HUMAN; HUMAN CELL; HUMAN TISSUE; IONIZING RADIATION; MAJOR CLINICAL STUDY; MOUSE; MOUTH CARCINOMA; NONHUMAN; ORAL SURGERY; PAPILLOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION EXPOSURE; RADIATION RESPONSE; REGULATORY MECHANISM; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; UPREGULATION; WILD TYPE;

EID: 38949212625     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00707.x     Document Type: Article

References (38)

1. Lowe SW, Cepero E, Evan G. Intrinsic tumor suppression. Nature 2004; 432: 307-15.
2. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643-9.
3. 1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 1994; 14: 6264-77.
4. +, the fission yeast homolog of Bin1, is dispensable for endocytosis or actin organization, but required for the response to starvation or genotoxic stress. Oncogene 2003; 22: 637-48.
5. Hammond EM, Dorie MJ, Giaccia AJ. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J Biol Chem 2003; 278: 12.207-13.
6. Cliby WA, Roberts CJ, Cimprich KA et al. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J 1998; 17: 159-69.
7. Ahn JY, Schwarz JK, Piwnica-Wrms H, Canman CE. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res 2000; 60: 5934-6.
8. Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998; 282: 1893-7.
9. Helt CE, Cliby WA, Keng PC, Bambara RA, O'Reilly MA. Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage. J Biol Chem 2005; 280: 1186-92.
10. Menoyo A, Alazzouzi H, Espin E, Armengol M, Yamamoto H, Schwartz S Jr. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res 2001; 61: 7727-30.
11. Matsuoka S, Nakagawa T, Matsuda A, Haruki N, Elledge SJ, Takahashi T. Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer. Cancer Res 2001; 61: 5362-5.
12. Staalesen V, Falck J, Geisler S et al. Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene 2004; 23: 8535-44.
13. 2 checkpoint control: Regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997; 277: 1501-5.
14. Bartkova J, Horejsi Z, Koed K et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434: 864-70.
15. Gorgoulis VG, Vassiliou LV, Karakaidos P et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434: 907-13.
16. Ohta M, Inoue H, Cotticelli MG et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996; 84: 587-97.
17. Huebner K, Garrison PN, Barnes LD, Croce CM. The role of the FHIT/FRA3B locus in cancer. Annu Rev Genet 1998; 32: 7-31.
18. Croce CM, Sozzi G, Huebner K. Role of FHIT in human cancer. J Clin Oncol 1999; 17: 1618-24.
19. Huebner K, Croce CM. FRA3B and other common fragile sites: The weakest links. Nat Rev Cancer 2001; 1: 214-21.
20. Ishii H, Zanesi N, Vecchione A et al. Regression of upper gastric cancer in mice by FHIT gene delivery. FASEB J 2003; 17: 1768-70.
21. Kuroki T, Trapasso F, Yendamuri S et al. Allele loss and promoter hypermethylation of VHL, RAR-β, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 2003; 63: 3724-8.
22. Fong LY, Fidanza V, Zanesi N et al. Muir-Torre-like syndrome in Fhit-deficient mice. Proc Natl Acad Sci USA 2000; 97: 4742-7.
23. Zanesi N, Fidanza V, Fong LY et al. The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci USA 2001; 98: 10.250-5.
24. Dumon KR, Ishii H, Vecchione A et al. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res 2001; 61: 4827-36.
25. Ishii H, Dumon KR, Vecchione A et al. Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res 2001; 61: 1578-84.
26. Roz L, Gramegna M, Ishii H, Croce CM, Sozzi G. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci USA 2002; 99: 3615-20.
27. Ottey M, Han SY, Druck T et al. Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant. Br J Cancer 2004; 91: 1669-77.
28. Hu B, Han S-Y, Wang X et al. Involvement of the Fhit gene in the ionizing radiation-activated ATR/CHK1 pathway. J Cell Physiol 2005; 202: 518-23.
29. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004; 73: 39-85.
30. Ishii H, Mimori K, Inoue H et al. Fhit modulates the DNA damage checkpoint response. Cancer Res, 2006; 66: 11.287-92.
31. Japan Society for Head and Neck Cancer. The General Rules for Clinical Studies on Head and Neck Cancer, 4th edn. Tokyo: Kanehara, 2005.
32. Marsh DJ, Zheng Z, Zedenius J et al. Differential loss of heterozygosity in the region of the Cowden locus within 10q22-23 in follicular thyroid adenomas and carcinomas. Cancer Res 1997; 57: 500-3.
33. Dacic S, Ionescu DN, Finkelstein S, Yousem SA. Patterns of allelic loss of synchronous adenocarcinomas of the lung. Am J Surg Pathol 2005; 29: 897-902.
34. Semba S, Trapasso F, Fabbri M et al. Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential. Oncogene 2006; 25: 2860-72.
35. Semba S, Han S-Y, Qin HR et al. Biological functions of mammalian Nit1, the counterpart of the invertebrate NitFhit Rosetta stone protein, a possible tumor suppressor. J Biol Chem 2006; 281: 28.244-54.
36. Siprashvili Z, Sozzi G, Barnes LD et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 1997; 94: 13.771-16.
37. Bianchi F, Magnifico A, Olgiati CE et al. FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells. Proc Natl Acad Sci USA 2006; 103: 18.981-6.
38. Durkin SG, Arlt MF, Howlett NG, Glover TW. Depletion of CHK1, but not CHK2, induces chromosomal instability and breaks at common fragile sites. Oncogene 2006; 25: 4381-8.